Compare SNCY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNCY | DBVT |
|---|---|---|
| Founded | 1982 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.5M | 769.4M |
| IPO Year | 2021 | N/A |
| Metric | SNCY | DBVT |
|---|---|---|
| Price | $15.29 | $17.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $19.00 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 737.6K | 601.3K |
| Earning Date | 02-02-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.51 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $1,106,213,000.00 | $5,502,000.00 |
| Revenue This Year | $6.16 | $1,768.71 |
| Revenue Next Year | $8.41 | $1,028.88 |
| P/E Ratio | $14.60 | ★ N/A |
| Revenue Growth | ★ 4.27 | N/A |
| 52 Week Low | $8.10 | $3.33 |
| 52 Week High | $18.59 | $26.19 |
| Indicator | SNCY | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 46.77 |
| Support Level | $14.19 | $16.49 |
| Resistance Level | $15.86 | $18.33 |
| Average True Range (ATR) | 0.49 | 1.20 |
| MACD | -0.01 | -0.51 |
| Stochastic Oscillator | 66.73 | 8.00 |
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.